Tetra Radar · FDA Approvals · Decision date
obexelimab: FDA decision date
Royalty Pharma plc (RPRX) · 27 May 2027
In August 2026, Zenas BioPharma announced that the FDA accepted for review its Biologics License Application for obexelimab for the treatment of immunoglobulin G4-related disease and assigned a PDUFA target action date of May 27, 2027.
Source: 10-Q of 4 November 2026
The decision is pending.
A PDUFA date is the date by which the FDA has said it will decide on an application. Dates can move, and a decision is not an approval. Tetra Radar observes public information for research purposes. It does not provide investment advice.